Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12167480 | 0.75 | — | — | |
| SCHEMBL12521557 | 0.74 | — | — | |
| SCHEMBL18561857 | 0.71 | HSD17B10 (0.43) | HSD17B10MAPTSMN1; SMN2NOS1RAB9A | |
| SCHEMBL4176951 | 0.70 | HSD17B10 (0.51) | HSD17B10MAPTSMN1; SMN2NOS1ALDH1A1 | |
| SCHEMBL4176948 | 0.70 | HSD17B10 (0.51) | HSD17B10MAPTSMN1; SMN2NOS1ALDH1A1 | |
| SCHEMBL16817446 | 0.70 | MAPT (0.64) | HSD17B10MAPTSMN1; SMN2NOS1RAB9A | |
| SCHEMBL4176954 | 0.70 | HSD17B10 (0.51) | HSD17B10MAPTSMN1; SMN2NOS1ALDH1A1 | |
| SCHEMBL15660784 | 0.70 | HSD17B10 (0.51) | HSD17B10MAPTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL13369199 | 0.70 | HSD17B10 (0.51) | HSD17B10MAPTSMN1; SMN2NOS1RAB9A | |
| SCHEMBL16817661 | 0.69 | MAPT (0.63) | HSD17B10MAPTSMN1; SMN2NOS1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | HSD17B10 3576/4885MAPT 3721/4885SMN1; SMN2 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.